Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trialMoshe Mittelman, Katharina Modelska, David H. Henry et al.|American Journal of Hematology|2024Cited by 17
Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group studyBożena Katarzyna Budziszewska, Ewa Lech‐Marańda, Jarosław Piszcz et al.|Leukemia & lymphoma/Leukemia and lymphoma|2014Cited by 13
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)Aleksandra Butrym, Grzegorz Mazur, Ewa Lech‐Marańda et al.|BMC Cancer|2015Cited by 7
Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn StudyMoshe Mittelman, Katharina Modelska, David H. Henry et al.|Blood|2023Cited by 5
Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive ChemotherapyMarta Libura, W Wiktor-Jędrzejczak, Karolina Karabin et al.|Cancers|2023Cited by 3